Appendix D

Table 8.1.2.B Summary of Serious Adverse Events by Preferred Terms, Hepatic Failure, Jaundice, Hepatitis NOS (Page 1 of 8)

Case No./ Country	Age Yrs	Gender	Length of Pravastatin Therapy	Description of Event	Outcome	Comments
Hepatic Failure						
10009074 France	73	M	Unk	Hospitalized for rhabdomyolysis, acute renal failure, hepatic failure, confusion, hemipareses	Death	
BO44052 UK	65	M	29 months continuous	Hospitalized for hepatic necrosis, hepatic failure and renal failure	Death	Coroners reported indicated cerebral edema secondary to hepatorenal failure and hepatic necrosis. Liver biopsy indicated acute hepatocytic degeneration
BO8254 Japan	64	M	5 weeks	Prolonged hospitalized for hemiplegia and cerebral infarction.	Resolved	Started pravastatin as in-patient. Developed fever and diclofenac started. Developed acute liver malfunction Diclofenac suspected
MO27532 US	21	F	23 days	Subject developed massive hepatic necrosis and liver failure	Death	History of severe congestive heart failure, ischemic bowel, lung mass, renal failure secondary to vasculitis secondary to Eminase therapy. MD states liver failure secondary to hypotension.
BO26167 Australia	Unk	Unk	48 months continuous	Hospitalized for exacerbation of chronic liver failure	Persists	History of alcoholic cirrhosis with ascites
MO55540 US	62	F	1 year continuous	Subject developed liver failure	Death	History of CAD, HTN, DM-II, GERD, Gallstones. MD states possible etiology for hepatitis related to drug toxicity pravachol, tylenol and ticlopidine
MO74549 US	58	F	7 month continuous	Hospitalized for sub-endocardial myocardial infarction. Pravastatin initiated as in-patient	Death	Subject seen in MDs office after initiation of pravastatin and noted to be jaundiced. Subject told to discontinue pravastatin but did not. Hospitalized for with liver failure
MO78251 US	Unk	M	5 month continuous	Hospitalized for nausea and abdominal pain	Death	Subject diagnosed with cancer of liver and pancreas

Table 8.1.2.B **Summary of Serious Adverse Events by Preferred Terms, Hepatic Failure, Jaundice, Hepatitis NOS (Page 2 of 8)**

Case No./ Country	Age Yrs	Gender	Length of Pravastatin Therapy	Description of Event	Outcome	Comments
Hepatic Failure (cont.)						
MO78777	64	F	4 month continuous	Hospitalized for jaundice, progressed to acute liver failure and coma	Death	History of diabetes for which subject was taking Rezulin. MD states events may be due to Rezulin therapy
MO82229	55	F	12 month continuous	Hospitalized for muscle pain, scleral icterus and elevated LFTs	Persists	
Jaundice						
BO006370 France	36	M	25 days continuous	Experienced jaundice 10 days after starting pravastatin 10 mg daily. Hospitalized for jaundice and hepatitis	Resolved	Final diagnosis was Epstein-Barr virus infection. Per MD there was no relationship between the event and pravastatin
BO06509 Japan	86	F	66 days continuous	Hospitalized for jaundice 2 months after taking pravastatin 10 mg	Resolved	Subject had previously been treated with simvastatin and pravastatin (10 months) without any hepatic function abnormalities
BO16119 UK	67	M	30 days continuous	Hospitalized for cholestatic jaundice	Resolved	Pretreatment hepatic enzymes elevated
BO16214 Belgium	73	F	6 weeks continuous	Hospitalized for icterus and hypochondrial pain 6 weeks after taking pravastatin 20 mg	Resolved	Subject underwent cholecystectomy
BO18823 Canada	Unk	Unk	2 year continuous	Hospitalized for jaundice	Resolved	Improved following placement of a shunt
BO24947 Spain	71	F	39 month continuous	Hospitalized for jaundice and increased LFTs	Resolved	Developed jaundice secondary to hyperbilirubinemia 13 days after changing cholesterol medication from pravastatin 20 to simvastatin 10 mg

Table 8.1.2.B Summary of Serious Adverse Events by Preferred Terms, Hepatic Failure, Jaundice, Hepatitis NOS (Page 3 of 8)

Case No./ Country	Age Yrs	Gender	Length of Pravastatin Therapy	Description of Event	Outcome	Comments
Jaundice (cont.)						
BO34337 Japan	69	F	5 year continuous	Hospitalized for jaundice	Resolved	History of anemia. Although subject had been taking pravastatin 15 mg and concomitant therapies for over 5 years, drug induced hepatic disorder suspected.
BO34784 Canada	73	M	a few years	Hospitalized for abnormal liver function tests, ascites, icteric skin jaundice and pneumothorax	Resolved	Pravastatin (20 mg) and iron dextran complex suspected
BO36871 Japan	60	F	38 months-continuous	Hospitalized due to jaundice	Resolved	ASAT & ALAT increased 15x ULN. Diclofenac concomitant therapy suspected as cause of hepatotoxicity.
BO37577 Japan	70	M	14 days – continuous	Hospitalized due to jaundice	Resolved	Pravastatin 10 mg daily started 2 weeks prior to subject suffering a cerebrovascular accident and discontinued after 3 weeks because of nausea and vomiting.
BO38142 Japan	48	F	4 months	Hospitalized for jaundice & increased total bilirubin levels	Resolved	History of biliary cirrhosis. Pravastatin 10mg daily for 13 weeks; increased to 20mg; then to 40mg. No improvement when pravastatin discontinued.
BO40491 Japan	73	F	3 months continuous	Developed jaundice	Resolved	Subject is Hepatitis C virus carrier
MO26246 US	Unk	M	Unk	Subject experienced jaundice and elevatated alk. phos.	Unk	Subject has pancreatic cancer. MD states no causal relationship to pravastatin
MO43024 US	62	M	1 year continuous	Hospitalized for jaundice and elevated bilirubin and ALAT	Resolved	History of alcohol abuse which ceased 10 years ago. Hepatitis screen negative.
MO51671	66	M	9 month continuous	Experienced jaundice and elevated LFTs	Persists	
MO73633	64	M	Unk	Hospitalized for jaundice and elevated LFTs		

Table 8.1.2.B Summary of Serious Adverse Events by Preferred Terms, Hepatic Failure, Jaundice, Hepatitis NOS (Page 4 of 8)

Case No./ Country	Age Yrs	Gender	Length of Pravastatin Therapy	Description of Event	Outcome	Comments
Hepatitis						
BO06370 France	36	M	25 days continuous	Hospitalized for jaundice and hepatitis	Resolved	Diagnosed with Epstein-Barr virus
BO07579 Japan	77	F	25 days	Hospitalized for hepatitis	Resolved	Diagnosed with drug induced hepatitis. Hepatic injury resolved after all medications stopped.
BO08205 France	66	F	5 weeks	Hospitalized for jaundice and hepatitis	Unk	
BO11127 Germany	63	F	20 day continuous	Hospitalized for cholecystitis and hepatitis	Unk	Diagnosed with cholelithiasis
BO15308 Canada	33	M	3 years	Hospitalized with hepatitis	Unk	Concomitant therapy with septra suspected drug
BO15516 France	64	F	Unk	Hospitalized with hepatitis	Unk	
BO16644 Australia	Unk	Unk	7 days	Hospitalized with hepatitis	Unk	
BO20172 Canada	45	M	1 month continuous	Hospitalized for icterus	Unk	Diagnosed with drug induced aplastic anemia secondary to hepatitis, bone marrow aplasia. Medicamentous hepatitis. Subject has a history of hepatitis A and icterus
BO28733 Japan	63	F	Unk	Hospitalized for acute hepatitis	Resolved	Pravastatin therapy reintroduced without liver function abnormalities
BO31940 Japan	61	F	8 weeks-continuous	Hospitalized with hepatitis NOS	Resolved	History of chronic liver disease and alcoholic fatty liver. Pretreatment, ALP and GGT elevated. Liver biopsy revealed changes consistent with drug-induced liver disease and fatty liver.

Table 8.1.2.B **Summary of Serious Adverse Events by Preferred Terms, Hepatic Failure, Jaundice, Hepatitis NOS (Page 5 of 8)**

Case No./ Country	Age Yrs	Gender	Length of Pravastatin Therapy	Description of Event	Outcome	Comments
Hepatitis (cont.)						
BO33900 France	67	M	7 month	Hospitalized for hepatitis, increased LFTs and jaundice	Resolved	
BO33987 France	71	M	Unk	Hospitalized for hepatitis		
BO34694	55	F	11 months continuous	Hospitalized for hepatitis		
BO35414 France	68	F	9 weeks	Hospitalized for coronary surgery, elevated LFTs noted as in-patient	Resolved	
BO35628 France	81	F	Unk	Developed abdominal pain and elevated LFTs	Resolved	Subject had biliary calculus . Drug relationship excluded
BO36203 France	75	M	5 year continuous	Developed jaundice, hepatitis diagnosed	Resolved	
BO36830 France	75	F	10 day continuous	Hospitalized for hepatitis		History of gallstones
BO37018 Japan	68	F	8 month continuous	Developed hepatitis		History of acute hepatitis. Drug induced hepatitis suspected
BO37792 Italy	56	F	6 weeks continuous	Hospitalized for toxic drug induced hepatits	Resolved	Drug induced hepatitis suspected. Hepatic injury resolved after all medications stopped
BO38412 France	46	M	19 days continuous	Developed cytolytic hepatitis	Persists	History of renal lithiasis, idiopathic hypercalcemia, MI

Table 8.1.2.B Summary of Serious Adverse Events by Preferred Terms, Hepatic Failure, Jaundice, Hepatitis NOS (Page 6 of 8)

Case No./ Country	Age Yrs	Gender	Length of Pravastatin Therapy	Description of Event	Outcome	Comments
Hepatitis (cont.)						
BO39000 France	47	M	Unk	Hospitalized for cytolytic hepatitis	Resolved	Diagnosed with microlithiasis, cholecystecomy performed
BO39512 France	54	F	6 months intermittent	Hospitalized with cholestatic hepatitis	Resolved	History of breast cancer
BO42062 Japan	53	F	5 weeks-continuous	Hepatitis	Resolved	Positive lymphocyte stimulation test for pravastatin.
BO43385 UK	65	F	6 months continuous	Developed hepatitis	Resolved	Drug induced hepatitis suspected. Hepatic injury resolved after all medications stopped. Suspected drug: Nitrofurantion for UTI
BO43478 Japan	64	F	3 months continuous	Hospitalized for elevated LFTs, malaise, anorexia	Resolved	Drug induced hepatitis suspected. Hepatic injury resolved after all medications stopped
BO45568 France	44	M	13 months continuous	Hospitalized for hepatitis	Resolved	pravastatin de-challenged. Drug relationship unable to determine
BO45589 France	71	F	5 day continuous	Hospitalized for cytolytic hepatitis and left ventricular insufficiency	Resolved	Drug induced hepatitis suspected. Hepatic injury resolved after all medications stopped.
BO45643 France	71	F	5 day continuous	Hospitalized for cytolytic hepatitis and left ventricular insufficiency	Resolved	Duplicate of BO45589, which will be deleted
BO45880 France	85	F	2 day continuous	Hospitalized for hepatitis	Resolved	Subject also taking simvastatin. Drug relationship unable to determine

Table 8.1.2.B Summary of Serious Adverse Events by Preferred Terms, Hepatic Failure, Jaundice, Hepatitis NOS (Page 7 of 8)

Case No./ Country	Age Yrs	Gender	Length of Pravastatin Therapy	Description of Event	Outcome	Comments
Hepatitis (cont.)						
MO24867 US	66	F	Unk	Hospitalized for elevated LFTs, jaundice, malaise, tiredness	Resolved	Drug induced hepatitis suspected. Suspected drugs: pravastatin and dyazide
MO34695 US	Unk	Unk	1 month	Hospitalized for hepatitis	Unk	Drug induced hepatitis suspected.
MO34964 US	70	F	10 days	Hospitalized for hepatitis	Unk	Drug induced hepatitis suspected. Prior therapy with lovastatin
MO48672 US	Unk	F	1 year intermittent	Hospitalized for acute renal failure and acute hepatitis	Resolved	History of gallstones. Pravastatin therapy not suspected.
MO57457 US	76	F	20 day continuous	Hospitalized for cholestasis and hepatic encephalopathy	Unk	Drug induced hepatitis suspected. pravastatin de-challenged.
MO57726 US	40	M	4 months	Hospitalized for hepatitis and aplastic anemia	Resolved	Prior therapy with lovastatin. Drug induced hepatitis suspected.
MO61427 US	79	F	Unk	Hospitalized for abnormal LFTs, weakness and muscle pain, nausea and diarrhea	Unk	Diagnosed with toxic hepatitis, rhabdomyolysis and azotemia. Pravastatin de-challenged
MO62885 US	Unk	Unk	Unk	Hospitalized for cholestatic hepatits	Unk	Drug induced hepatitis suspected
MO64164 US	73	M	6 weeks	Hospitalized for jaundice, ascites and hepatomegly	Resolved	Drug induced hepatitis suspected. pravastatin de-challenged.
MO65930 US	Unk	Unk	Unk	Hospitalized with hepatic cirrhosis. Also developed hepatitis	Unk	History of alcohol abuse questionable. Other factors suspected

Table 8.1.2.B Summary of Serious Adverse Events by Preferred Terms, Hepatic Failure, Jaundice, Hepatitis NOS (Page 8 of 8)

Case No./ Country	Age Yrs	Gender	Length of Pravastatin Therapy	Description of Event	Outcome	Comments
Hepatitis (cont.)						
MO68846 US	48	M	~ 5 years	Developed hepatitis following previous admission for MI	Resolved	
MO79707 US	75	M	6 years continuous	Developed hepatitis	Resolved	History of hepatitis A and moderate alcohol use. Event determined to be a chemically induced hepatitis – autoimmune disorder
MO80630 US	64	M	20 month continuous	Developed hepatitis	Resolved	Taking pravastatin and rezulin therapy
MO91154 US	66	M	6 month continuous	Hospitalized for hepatitis	Unk	Initially diagnosed as drug induced toxic hepatitis. Reinvestigation for parasitic disease confirmed